Dr. Howard Smith Oncall

  Vidcast:  https://youtu.be/86KVmVr9E_c   Several weeks ago I reported that Ozempic for type 2 diabetes drives modest but significant weight loss.  Now an international collaborative randomized clinical trial confirms it and shows drug continuation stabilizes the weight loss and other benefits.   A 902 participant group was studied in 10 countries.  Following a 20 week initial course, there was a mean weight loss of 11% with proportional drops in waist circumference and blood pressure.  Those continuing the drug over another 48 weeks had an additional 8% weight loss while those stopping drug had a 7% weight gain.   Semaglutide may turn out to be a useful weapon in the worldwide battle against obesity.   https://jamanetwork.com/journals/jama/fullarticle/2777886   #semaglutide #ozempic #obesity #weightloss #diabetes